SC
Stempoint Capital Portfolio holdings
AUM
$311M
This Quarter Return
+12.42%
1 Year Return
+15.22%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$333M
AUM Growth
+$333M
(-1.9%)
Cap. Flow
-$32.9M
Cap. Flow
% of AUM
-9.87%
Top 10 Holdings %
Top 10 Hldgs %
56.09%
Holding
63
New
21
Increased
10
Reduced
17
Closed
13
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$14.2M |
| 2 |
Incyte
INCY
|
$8.56M |
| 3 |
Praxis Precision Medicines
PRAX
|
$8.33M |
| 4 |
Arcutis Biotherapeutics
ARQT
|
$7.56M |
| 5 |
Day One Biopharmaceuticals
DAWN
|
$7.06M |
Top Sells
| 1 |
Arcellx
ACLX
|
$18.4M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
$17.2M |
| 3 |
Immunocore
IMCR
|
$11.5M |
| 4 |
Merck
MRK
|
$10.2M |
| 5 |
Immunovant
IMVT
|
$9.72M |
Sector Composition
| 1 | Healthcare | 99.55% |
| 2 | Financials | 0.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
IDEAYA Biosciences
IDYA
$2.15B
| $4.2M | 1.26% |
132,703
+30,916
| +30% | +$979K |
|
27
Terns Pharmaceuticals
TERN
$609M
| $3.75M | 1.12% |
+449,321
| New | +$3.75M |
|
28
Perspective Therapeutics
CATX
$250M
| $3.18M | 0.95% |
238,084
-105,726
| -31% | -$1.41M |
|
29
Pyxis Oncology
PYXS
$79.4M
| $3.12M | 0.93% |
850,210
-352,465
| -29% | -$1.29M |
|
30
Neurogene
NGNE
$264M
| $3.08M | 0.92% |
73,299
-5,302
| -7% | -$222K |
|
31
UroGen Pharma
URGN
$900M
| $3.07M | 0.92% |
+241,984
| New | +$3.07M |
|
|
VIGL
32
DELISTED
Vigil Neuroscience
VIGL
| $2.53M | 0.76% |
743,719
-693
| -0.1% | -$2.36K |
|
33
Wave Life Sciences
WVE
$1.53B
| $2.46M | 0.74% |
+300,000
| New | +$2.46M |
|
34
BridgeBio Pharma
BBIO
$9.89B
| $2.42M | 0.72% |
+94,885
| New | +$2.42M |
|
35
Janux Therapeutics
JANX
$1.37B
| $2.24M | 0.67% |
49,415
-43,534
| -47% | -$1.98M |
|
36
Surrozen
SRZN
$104M
| $2.19M | 0.66% |
182,918
+39,408
| +27% | +$472K |
|
37
Rhythm Pharmaceuticals
RYTM
$6.85B
| $2.16M | 0.65% |
+41,268
| New | +$2.16M |
|
|
BBOT
38
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$708M
| $2.09M | 0.63% |
200,000
| – | – |
|
39
Sarepta Therapeutics
SRPT
$1.78B
| $1.88M | 0.56% |
+15,014
| New | +$1.88M |
|
40
Protara Therapeutics
TARA
$120M
| $1.73M | 0.52% |
942,857
-41,256
| -4% | -$75.5K |
|
|
PCSC
41
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $1.5M | 0.45% |
150,000
| – | – |
|
42
Tourmaline Bio
TRML
$601M
| $1.43M | 0.43% |
+55,523
| New | +$1.43M |
|
43
Capricor Therapeutics
CAPR
$287M
| $1.42M | 0.43% |
+93,638
| New | +$1.42M |
|
44
Alkermes
ALKS
$4.78B
| $1.37M | 0.41% |
+48,918
| New | +$1.37M |
|
|
CNTA
45
Centessa Pharmaceuticals
CNTA
$2.25B
| $1.34M | 0.4% |
+83,662
| New | +$1.34M |
|
|
MBX
46
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $1.3M | 0.39% |
+50,000
| New | +$1.3M |
|
47
Cytokinetics
CYTK
$4.23B
| $764K | 0.23% |
+14,464
| New | +$764K |
|
48
Revolution Medicines
RVMD
$7.1B
| $755K | 0.23% |
+16,654
| New | +$755K |
|
49
Astria Therapeutics
ATXS
$349M
| $619K | 0.19% |
+56,287
| New | +$619K |
|
50
Edgewise Therapeutics
EWTX
$1.51B
| $531K | 0.16% |
19,900
-251,157
| -93% | -$6.7M |
|